Contribution of genetic polymorphism in
ABCB1
Imatinib
gastrointestinal stromal tumor (GIST)
single-nucleotide polymorphism (SNP)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
19
03
2024
accepted:
18
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
17
5
2024
Statut:
ppublish
Résumé
Imatinib mesylate (IM) is a first-line treatment option for the majority of patients diagnosed with gastrointestinal stromal tumors (GISTs). Although the clinical benefit is high, interindividual response is variable. This study thus aimed to assess how genetic polymorphisms can affect the blood levels of IM and treatment outcomes in patients with GIST. A total of 31 single-nucleotide polymorphisms (SNPs) in selected cytochrome P450 ( With a mean follow-up of 75.99 months, trough concentrations of imatinib were examined at average time points of 7.73 for each patient. Polymorphism in This is the largest cohort study evaluating the associations of SNP and imatinib blood trough levels. The
Sections du résumé
Background
UNASSIGNED
Imatinib mesylate (IM) is a first-line treatment option for the majority of patients diagnosed with gastrointestinal stromal tumors (GISTs). Although the clinical benefit is high, interindividual response is variable. This study thus aimed to assess how genetic polymorphisms can affect the blood levels of IM and treatment outcomes in patients with GIST.
Methods
UNASSIGNED
A total of 31 single-nucleotide polymorphisms (SNPs) in selected cytochrome P450 (
Results
UNASSIGNED
With a mean follow-up of 75.99 months, trough concentrations of imatinib were examined at average time points of 7.73 for each patient. Polymorphism in
Conclusions
UNASSIGNED
This is the largest cohort study evaluating the associations of SNP and imatinib blood trough levels. The
Identifiants
pubmed: 38756645
doi: 10.21037/jgo-24-188
pii: jgo-15-02-577
pmc: PMC11094496
doi:
Types de publication
Journal Article
Langues
eng
Pagination
577-584Informations de copyright
2024 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-188/coif). The authors have no conflicts of interest to declare.